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GABAA receptors (GABAARs) are the major inhibitory neurotransmitter receptors in the
brain and are therapeutic targets for many indications including sedation, anesthesia
and anxiolysis. There is, however, considerable scope for the development of new
therapeutics with improved beneficial effects and reduced side-effect profiles. The
anthelminthic drug, ivermectin, activates the GABAAR although its binding site is
not known. The molecular site of action of ivermectin has, however, been defined
by crystallography in the homologous glutamate-gated chloride channel. Resolving
the molecular mechanisms of ivermectin binding to α1β2γ2L GABAARs may provide
insights into the design of improved therapeutics. Given that ivermectin binds to subunit
interfaces, we sought to define (1) which subunit interface sites it binds to, (2) whether
these sites are equivalent in terms of ivermectin sensitivity or efficacy, and (3) how many
must be occupied for maximal efficacy. Our approach involved precluding ivermectin
from binding to particular interfaces by introducing bulky M3 domain 36′F sidechains to
the “+” side of those interfaces. We thereby demonstrated that ivermectin produces
irreversible channel activation only when it binds to the single γ2L-β2 interface site.
When it binds to α1-β2 sites it elicits potentiation of GABA-gated currents but has no
irreversible activating effect. Ivermectin cannot bind to the β2-α1 interface site due to its
endogenous bulky 36′ methionine. Replacing this with an alanine creates a functional
site at this interface, but surprisingly it is inhibitory. Molecular docking simulations reveal
that the γ2L-β2 interface forms more contacts with ivermectin than the other interfaces,
possibly explaining why ivermectin appears to bind irreversibly at this interface. This
study demonstrates unexpectedly stark pharmacological differences among GABAAR
ivermectin binding sites.
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Introduction
Receptors of the pentameric ligand-gated ion channel (pLGIC) family mediate fast synaptic
neurotransmission in the nervous system. In vertebrates, the pLGIC family includes the anion-
permeable glycine receptor (GlyR) and GABA type-A receptor (GABAAR) and the cation-
permeable nicotinic acetycholine receptor (nAChR) and serotonin type-3 receptor (5-HT3R).
Invertebrate species are known to express a variety of other pLGIC receptor subtypes, including
a glutamate-gated chloride channel receptor (GluClR). pLGICs comprise five subunits arranged
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in a ring to form a central water-filled pore that spans the cell
membrane. Each subunit can be divided into three functional
domains. The extracellular domain contains the binding sites
for the neurotransmitter agonists. The transmembrane domain
comprises twenty α-helices (four per subunit) arranged in
concentric layers around a central aqueous pore, with M2
directly lining the permeation pathway, M1 and M3 shielding
M2 from the surrounding lipid bilayer, and M4 being the
outermost segment. As detailed below, the transmembrane
region provides the binding sites for hydrophobic ligands
such as alcohols, anesthetics and macrocyclic lactones such
as ivermectin. The third receptor domain is intracellular and
contains phosphorylation sites and binding sites for synaptic
clustering proteins.
Most members of the human pLGIC family are targeted by
drugs of major therapeutic importance. GABAARs, for example,
are established therapeutic targets for alcohol withdrawal, muscle
relaxation, sedation, anaesthetia, seizure control and anxiolysis,
although there is considerable scope for the development of
new therapeutics with improved beneficial effects and a reduced
propensity for dependency and other side-effects.
The gold standard anthelmintic drug, ivermectin, is widely
used for controlling filarial and arthropod parasitic infestations
in humans, livestock and agriculture (Crump and Omura, 2011;
Campbell, 2012). Its biological target is the GluClR, a pLGIC
that is highly expressed in nerve and muscle cells of nematodes
and arthropods, but absent in vertebrate species. Low nanomolar
concentrations of ivermectin irreversibly activate a chloride
influx through these GluClRs that electrically silences nerve and
muscle activity, leading to death by flaccid paralysis or starvation
(Wolstenholme and Rogers, 2005). Importantly, ivermectin and
related compounds also bind to and either directly activate or
positively modulate several vertebrate pLGICs including GlyRs
(Shan et al., 2001; Lynagh and Lynch, 2010; Lynagh et al., 2011),
GABAARs (Sigel and Baur, 1987; Krüsek and Zemková, 1994;
Adelsberger et al., 2000), and α7 nAChRs (Krause et al., 1998),
albeit at relatively low potencies. Ivermectin also activates the
structurally-unrelated P2X4 cation channel (Khakh et al., 1999).
A 3.3 Å crystal structure of ivermectin docked to the C. elegans
α GluClR has recently been published (Hibbs and Gouaux,
2011; Althoff et al., 2014). Although this structure clearly defines
the orientation of ivermectin in its site, a functional analysis
of ivermectin-receptor interactions in the human GlyR and
amino acid sequence comparisons of ivermectin-sensitive and
ivermectin-insensitive pLGICs from various phyla suggest that
the molecular interactions mediating ivermectin binding remain
to be delineated (Lynagh and Lynch, 2012a,b).
Understanding themolecular interactions between ivermectin
and its binding sites on the GABAARmay define new therapeutic
pharmacophores that could be useful in the design of improved
treatments for neurological disorders such as those listed above.
Themost abundant GABAAR subtype in the brain is formed from
α1, β2, and γ2L subunits in a β2-α1-β2-α1-γ2L stoichiometry in
an anticlockwise orientation when viewed toward the membrane
from the extracellular membrane side (Sieghart and Sperk,
2002; Gallagher et al., 2004; Olsen and Sieghart, 2009). Given
that ivermectin binds at subunit interfaces (Lynagh and Lynch,
2012a), this stoichiometry implies four structurally distinct sites
per receptor. Although we know that ivermectin activates these
receptors (Adelsberger et al., 2000), we do not know (1) which
subunit interface sites it binds to, (2) whether these structurally
distinct sites are equivalent in terms of ivermectin sensitivity or
efficacy, or (3) how many of them must be occupied for maximal
ivermectin efficacy. In addition, it has been shown that large
sidechains at the 36′ position in the M3 domain block ivermectin
access to its site in the α1 GlyR and α3β GluClR (Lynagh and
Lynch, 2010; Lynagh et al., 2011). It is currently unclear whether
this also applies to the GABAAR, and resolving this would help
confirm whether ivermectin binds to GABAARs in the same
orientation as it binds to GluClRs. Here we sought to address all
these questions by investigating heterologously expressed human
α1β2γ2L GABAARs that incorporate site-directed mutations to
36′ residues with the aim of constraining ivermectin binding to
defined interfaces. The effects of ivermectin on mutant receptors
are quantitated via patch clamp electrophysiology and the results
are interpreted with the aid of molecular structural modeling and
computational ligand docking.
Materials and Methods
Chemicals
Ivermectin andGABAwere obtained from Sigma-Aldrich. Stocks
of 10mM ivermectin were dissolved in dimethyl sulfoxide and
stored at −20◦C. GABA was maintained as a 100mM stock in
water.
Molecular Biology
The human α1, β2, and γ2L GABA subunit cDNAs were
independently subcloned into the pcDNA3.1 plasmid vector
(Life Technologies, Waltham, MA). Site-directed mutagenesis
was done using the QuikChange mutagenesis kit (Agilent, Santa
Clara, CA). Successful incorporation of all the mutants was
confirmed by DNA sequencing.
HEK-293 Cell Culture and Transfection
HEK-293 cells were cultured in Dulbecco’s modified Eagle’s
medium (Life Technolgies, Waltham, MA) containing
penicillin/streptomycin (Sigma-Aldrich, St. Luis, MO) and
Fetal Bovine Serum (HyClone, Logan, UT), and split onto
glass coverslips in 60mm dishes. On the next day, cells were
transiently transfected with the GABAAR cDNAs of interest
(at a plasmid transfection ratio of 1α1:1β2:3γ2L) and an empty
pEGFP vector (Clontech, Mountainview, CA) as a fluorescent
transfection marker via a calcium phosphate method.
Patch Clamp Electrophysiology
Transfected cells on glass coverslips showing GFP fluorescence
were used in experiments. Patch clamp pipettes were pulled
from borosilicate glass capillary tubes (Hirschmann Laborgeräte,
Eberstadt, Germany) using a horizontal pipette puller (P97,
Sutter Instruments, Novato, CA) and had tip resistances of 1.5–
3.5M when filled with intracellular solution, consisting of (in
mM): 145CsCl, 2 CaCl2, 2MgCl2, 10 HEPES, and 5 EGTA,
adjusted to pH 7.4 with CsOH. Extracellular solution consisted of
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(in mM): 140NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10
D-glucose, adjusted to pH 7.4 with 2MNaOH. Cells were voltage-
clamped at −70mV in the whole-cell recording configuration
and membrane currents were recorded using Axon Multiclamp
700B amplifier and pClamp 10 software (Molecular Devices,
Sunnyvale, CA). Membrane currents were filtered at 500Hz
and digitized at 2 kHz. Solutions for experiments were prepared
from stocks on the day of recording. Solutions were applied to
cells via a purpose-built gravity-fed perfusion system fabricated
from polyethylene tubing. Experiments were conducted at room
temperature (19–22◦C). Applying increasing concentrations of
drugs to cells generated GABA, and ivermectin concentration-
response relations as outlined below.
Molecular Modeling and Docking
The crystal structure of the C. elegans α GluClR in the wide-open
pore conformation in complex with ivermectin and glutamate
(PDB entry 3RIF; Hibbs and Gouaux, 2011), was used as a
template for the homology modeling of the human GABA
subunits α1, β2, and γ2L, as well as the Single-Point Mutants:
α1A36
′F, β2M36
′A, and γ2LS36
′F. The sequence of the human
GABAAR subunits α1 (Uniprot entry P14867), β2 (P47870), and
γ2L (P18507) were aligned with the GluClR sequence using
ClustalW. Each GABAAR subunit modeling was performed with
TABLE 1 | Concentration-response curve fit parameters for GABA at wild
type and mutant GABAARs.
GABA receptor GABA EC50 (µM) nH Imax(nA) n
α1β2γ2L (wild type) 0.92±0.19 1.4±0.2 3.2±0.6 5
α1A36
′F β2γ2L 0.13±0.01 2.1±0.1 3.5±1.5 4
α1β2γ2LS36
′F 4.42±0.17*** 1.4±0.1 3.6±1.1 4
α1A36
′F β2γ2LS36
′F 4.38±0.12*** 1.5±0.1 3.8±1.3 5
α1β2 0.80±0.03 1.1±0.2 1.8±0.5 4
α1A36
′F β2 0.13±0.01 2.1±0.1 2.5±0.5 4
α1β2M36
′Aγ2L 0.76±0.02 0.9±0.1 2.9±0.6 5
α1A36
′Fβ2M36
′Aγ2LS36
′F 2.62±0.03*** 0.9±0.1 3.0±0.6 4
***P < 0.001 using One-Way ANOVA Dunnett’s with multiple comparisons test.
FIGURE 1 | Ivermectin modulation of wild type α1β2γ2L GABAARs. In this and subsequent figures, all displayed traces were recorded from HEK293 cells
expressing WT or mutated α1β2γ2L receptors using whole cell recording, and the durations of ivermectin and GABA applications are indicated by gray and black
bars, respectively. (A) Sample recording showing the effect of repeated applications of EC3 GABA together with increasing concentrations of ivermectin at 1min
intervals as indicated. A current response to saturating GABA from the same cell is also shown. (B) Averaged ivermectin concentration-response relationships from 4
to 5 cells, with error bars shown as SEM. Ivermectin-induced reversible and irreversible currents, measured as shown in (B), are plotted separately as circles and
squares, respectively. (C) Mean saturating magnitudes of reversible and irreversible ivermectin-modulated currents (defined as indicated in A), and their sum, plotted
as a percentage of the saturating GABA-activated current. Mean GABA EC50, nH and Imax values for this and all other constructs are provided in Table 1.
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Modeler 9.10 (Sali and Blundell, 1993). One hundred models
of each subunit were generated and ranked according to their
DOPE scores. The respective WT or mutant α1 and β2 subunits
were projected twofold and the γ2L subunit one-fold, using
the coordinates of GluClR in order to assemble the respective
pentamer. Eachmodel with the lowest score was selected and was
checked with the “What if ” (swift.cmbi.ru.nl), and MolProbity
(smb.slac.stanford.edu) protein structure validation servers. For
the docking, the PDB was prepared as a “ICM object” using
the ICM Pocket Finder method in the Internal Coordinate
Mechanics software (ICM-Pro Molsoft LLC, San Diego, CA),
identifying three common binding pockets in the α1-β2, α1-
γ2L, γ2L-β2, and the mutant β2M36
′A-α interfaces: one pocket
in the extracellular domain and two in the transmembrane
domains of the model. One of the transmembrane domain
pockets corresponded with the Ivermectin Binding Site reported
for the GluCl receptor, this pocket was used for all the
following tests. Ivermectin was loaded from the ChemSpider
database (ID 16736314) and was docked in the assigned pocket
interface using the flexible docking ICM-biased probability
Monte Carlo (BPMC) method. Three independent docking runs
were performed for each interface of the GABAA receptor model
with the length of the docking simulation adjusted by the
default thoroughness value (thoroughness = 1). The docking
poses were selected on the basis of their docking scores and if
appropriate the capacity of forming hydrogen bonds between
the ligand and the receptor. The program predicted similar
binding poses for the most sites of each interface with the
molecule of IVM, the average difference between the highest
and the lowest Root Mean Square Deviation (RMSD) predictions
for all of the interacting residues that are common to all four
interface binding sites was ∼2 Angstrom. Each molecule of
ivermectin docked was manually inspected in its docked pose
for receptor residues in each interface making contact lower
FIGURE 2 | Molecular modeling of ivermectin binding to its subunit interface binding sites in the α1β2γ2L GABAAR. (A) Amino acid sequence alignment of
M3 residues of the human α1, β2, and γ2L GABAAR subunits, the human α1 GlyR subunit and the C. elegans α GluClR subunit with their respective 36
′ residues
highlighted in a box. (B) Molecular structural model of the transmembrane domains of a wild type β2-α1-β2-α1-γ2L GABAARviewed from the extracellular side of the
membrane along the pore axis. This receptor accommodates three ivermectin molecules (green) in their subunit interface binding sites. In this and subsequent model
structures, the pore location is denoted by the red dashed circle, 36′ sidechains and bound ivermectin molecules (green) are shown in stick form and interfaces that
do not bind ivermectin are indicated by a red X. (C) This panel shows the effect of mutagenesis on the ability of ivermectin to bind at individual interfaces. The left
column displays single subunit interfaces formed from (top to bottom) α1-β2, α1-γ2L, γ2L-β2, and β2-α1 interfaces, with ivermectin docked where possible. The right
column shows the same four subunit interfaces incorporating the indicated mutations (A36′F, S36′F, or M36′A).
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than a spatial chemical distance of 5Å2 using the contact area
function of the ICM-Pro software, this distance satisfices the
requirements for the formation of hydrogen bonds, disulfide
bonds, salt bridges and hydrophobic interactions. The ligand-
protein model complex was saved in PDB format and images
were rendered using ICM-Pro software and the Pymol Molecular
Graphics System, Version 1.3 (Schrodinger, 2010).
Statistical Analysis
GABA and ivermectin concentration-response experiments
were performed as described below. For each GABA
concentration-response experiment, the half-maximal agonist
concentration (EC50), Hill coefficient (nH) and saturating current
magnitude (Imax) values were determined by fitting individual
concentration-response relationships with the 3-parameter Hill
equation (Prism 6.0, GraphPad Software Inc., San Diego, CA,
USA). Results are expressed as mean ± S.E.M from at least 3
experiments. Ivermectin concentration-response relations were
normalized relative to the GABA-activated Imax in the same cell
and then expressed as mean ± S.E.M from 3 to 6 experiments.
Ivermectin concentration-response relations were fitted with
cubic spine curves. In all experiments, ANOVAs or t-tests,
as appropriate, were used to compare indicated values with
P < 0.05 representing significance.
Results
Effects of Ivermectin on Wild Type α1β2γ2L
GABAARs
Ivermectin concentration-response relationships were
determined by applying ivermectin at progressively increasing
concentrations (0.1, 0.3, 1, 3, 10, and 30µM) for 10 s periods
at 1min intervals. An EC3 concentration of GABA was co-
applied with ivermectin for the second 5 s period of every 10 s
application. A sample recording from α1β2γ2L GABAARs using
this protocol is shown in Figure 1A. Under these conditions,
ivermectin induced both a potentiation of the reversible GABA-
gated current plus an irreversibly-activated current component.
Mean concentration-response relationships for both responses
were normalized to the saturating GABA-gated current in the
same cell and plotted separately (Figure 1B). In addition, the
mean saturating magnitudes of the reversible and irreversible
current components relative to the saturating GABA-gated
current magnitude in the same cell are plotted in Figure 1C.
Throughout the rest of this study we quantitated the effects of
ivermectin as illustrated in Figure 1B.
Control of Ivermectin Binding to Subunit
Interface Sites
A previous study showed that the volume of the M3 residue at
36′ position (numbered according to the standard M2 domain
residue numbering system) is a crucial determinant of ivermectin
sensitivity in both the human α1 GlyR and the H. contortus
α3β GluClR (Lynagh and Lynch, 2010). In both receptors, 36′G
resulted in exquisite (low nanomolar) ivermectin sensitivity,
36′S and 36′A produced receptors with high nanomolar—low
micromolar sensitivity, whereas larger residues (notably 36′F)
eliminated ivermectin sensitivity entirely. As the 36′ sidechain
lines the mouth of the ivermectin site on the “+” side of
the subunit interface (Hibbs and Gouaux, 2011), it is likely
that a large volume sidechain at this position sterically hinders
ivermectin from entering its site (Lynagh et al., 2011; Lynagh
and Lynch, 2012a). A sequence alignment of the α1, β2, and γ2L
GABAAR subunits predicts that the α1 and γ2L subunits, which
contain 36′A and 36′S, respectively, should support ivermectin
binding sites but the β2 subunit, which contains a 36′M, should
not (Figure 2A). In support of this, molecular modeling of
ivermectin binding to the α1β2γ2L GABAAR reveals that it is
TABLE 2 | Transmembrane residues predicted to contribute to ivermectin
sensitivity in the C. elegans α GluClR and the human α1β2M36
′Aγ2L
GABAAR.
α
GluClR
α1
GABAAR
β2M36
′A
GABAAR
γ2L
GABAAR
M1 POSITION
−16′ Ile Ile Ile
RMSD = 0.2 Å
Val
RMSD = 0.2 Å
−19′ Met Met
RMSD = 0.4 Å
Leu
RMSD = 0.1 Å
Leu
RMSD = 0.6 Å
−20′ Cys Ile Ile
RMSD = 0.1 Å
Thr
RMSD = 0.6 Å
−22′ Pro Pro
RMSD = 0.2 Å
Pro
RMSD = 0.1 Å
Pro
RMSD = 0.1 Å
−23′ Ile Leu
RMSD = 0.1 Å
Met
RMSD = 0.2 Å
Ile
RMSD = 0.6 Å
−26 Gln Gln Gln
RMSD = 0.1 Å
Gln
−27′ Leu*
2.5 Å-C7OH
Ile*
2.6 Å-C7OH
RMSD = 0.1 Å
Leu*
2.6 Å-C7OH
RMSD = 0.1 Å
Ile*
2.5 Å-C7OH
RMSD = 0.5 Å
M2 POSITION
12′ Thr Thr
RMSD = 0.1 Å
Thr
RMSD = 0.1 Å
Thr
RMSD = 0.1 Å
15′ Ser*
2.6 Å-C5OH
Ser*
RMSD = 0.1 Å
2.8 Å-C5OH
Asn
RMSD = 1.2 Å
Ser*
RMSD = 0.4 Å
2.8 Å-C5OH
16′ Ala Ile
RMSD = 0.4 Å
Thr Thr
RMSD = 0.4 Å
M3 POSITION
28′ Ile Ala Val
RMSD = 0.8 Å
Val
RMSD = 0.4 Å
32′ Asp Asp Asp
RMSD = 1.5 Å
Asp
RMSD = 1.6 Å
36′ Gly Ala
RMSD = 0.1 Å
Ala
RMSD = 0.1 Å
Ser
RMSD = 0.3 Å
39′ Met Tyr
RMSD = 0.4 Å
Phe
RMSD = 0.7 Å
Phe
RMSD = 0.9 Å
40′ Thr Ala Val
RMSD = 0.5 Å
Ile
RMSD = 0.3 Å
Residues in gray are predicted not to bind ivermectin. The number below each residue
represents the Root Mean Square Deviation (RMSD) in residue position calculated
from three independent docking simulations. *Residues forming H-bonds with hydroxyls
attached to carbons C5 or C7 of the ivermectin molecule. The distances between the
participating hydrogens are indicated. The values shown in bold are the distances in
Angstroms between the residues forming H-bonds.
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able to dock into sites at the α1-β2, α1-γ2L, and γ2L-β2 interfaces
but not at the β2-α1 interface (Figure 2B). In agreement with
this, a recent study on an insect RDL homomeric GABAAR
also found that the G36′M mutation eliminated ivermectin
sensitivity (Nakao et al., 2015). We introduced the A36′F and
S36′F mutations into the α1 and γ2L subunits, respectively,
with the aim of eliminating existing ivermectin sites. We also
introduced the M36′A mutation into the β2 subunit which we
predicted would decrypt a possible site at the β2-α1 interface.
According to our molecular modeling simulations, the A/S36′F
mutations eliminated ivermectin binding whereas the M36′A
mutations created an ivermectin site (Figure 2B). Of course,
these predictions need to be validated by functional analysis.
However, before presenting the functional analysis, we
describe in more detail the molecular interactions predicted to
exist at each interface site. Table 2 provides a summary of all
transmembrane α1β2M36
′Aγ2L GABAAR residues predicted to
interact with ivermectin in our model structure. Corresponding
ivermectin binding residues from the C. elegans α GluClR
crystal structure (Hibbs and Gouaux, 2011) are also displayed.
Residues in gray are predicted not to bind ivermectin, whereas
asterisked residues are predicted to form hydrogen bonds with
ivermectin. The spatial orientations of these residues relative to
docked ivermectin are depicted in Figure 3. Note that Figure 3A
only displays those interacting residues that are common to
all four interface binding sites. The additional interacting
residues relevant to particular interfaces are shown in Figure 3B.
According to Figure 3, the α1-β2 and α1-γ2L interfaces are
structurally similar, with ivermectin-interacting residues sharing
similar characteristics of polarity and hydrophobicity. On the
other hand, the γ2L-β2 interface shows a greater number
of residues contributing polar contacts that should result
in the pocket forming tighter contacts around the bound
ivermectin molecule. The decrypted β2-α1 interface has a
similar number of contacts as the α1-β2 and α1-γ2L interfaces,
although their spatial distribution patterns differ significantly
(Figure 3B).
GABA Concentration-response Relationships
The mean GABA concentration-response relationships for
all wild type and mutant GABAAR subunit combinations
investigated in this study are displayed in Figure 4, with mean
FIGURE 3 | Ivermectin contact residues. (A) This panel shows ivermectin bound at the α1-β2 interface, viewed from within the plane of the membrane from the (−)
side of the interface (left panel) and the (+) side of the interface (right panel). Note it only displays interacting residues that are common to all four interface binding
sites. (B) This panel shows additional interacting residues, relevant to particular interfaces only. For example, at the β2 (−) interface, ivermectin interacts with a total of
7 residues (4 depicted in A and 3 depicted in B).
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FIGURE 4 | Mean agonist concentration-response relationships of all
GABAAR subunit combinations investigated in this study. The wild type
α1β2γ2L data, shown as blue points and red curve fits, are reproduced in all
panels to facilitate comparison between panels. All data points were averaged
from 4 to 6 cells and individual concentration-response curves were fitted by
the Hill equation. The mean Hill equation parameters of best fit are
summarized in Table 1.
parameters of best fit to the Hill equation summarized in Table 1.
Of particular note, the α1A36
′F mutation caused a dramatic
reduction in the GABAEC50 value whereas the γ2LS36
′F mutation
had the opposite effect. This later effect provides strong evidence
for the efficient incorporation of γ2L subunits into ternary
receptors.
Properties of α1A36
′Fβ2γ2L GABAARs
According to our molecular modeling, the α1A36
′F mutation
blocks ivermectin binding at the α1-β and α1-γ2L interfaces,
leaving the γ2L-β2 interface as the only available ivermectin
site (Figure 5A). A sample recording, showing the effect
of increasing ivermectin concentrations on EC3 GABA-gated
currents on α1A36
′Fβ2γ2L GABAARs, reveals both reversible
(i.e., potentiating GABA-activated currents) and irreversible
current increases (Figure 5B). The mean concentration-response
relationship for the reversible current revealed no change
in ivermectin sensitivity relative to the wild type receptor,
although the saturating magnitude of the potentiation was
significantly reduced (Figure 5C). The mean concentration-
response of the irreversible current revealed a significantly larger
peak current relative to that observed the wild type receptor
(Figure 5D). Plotting the saturating reversible and irreversible
current magnitudes as a percentage of themean saturating GABA
current supported these findings (Figure 5E). The main result
is a significant increase in the ivermectin-induced irreversible
current component in α1A36
′Fβ2γ2L GABAARs relative to wild
type GABAARs (Figure 5E).
Properties of α1β2γ2LS36
′F and α1A36
′Fβ2γ2LS36
′F
GABAARs
According to our modeling, α1β2γ2LS36
′F GABAARs should
contain ivermectin sites at the α1-β2 and α1-γ2L interfaces
only (Figure 6A). As shown in Figure 6B, ivermectin enhanced
GABA-gated currents but induced no irreversible activation
of these GABAARs. The averaged concentration-response
relationship of the reversible potentiation revealed a reduction in
its peak magnitude relative to the wild type receptor (Figure 6E),
but no significant difference to that observed at the α1A36
′Fβ2γ2L
GABAAR (P > 0.05, unpaired t-test). This similarity in
potentiating efficacy may mean that the γ2L-β2 interface is
functionally equivalent to the α1-β2 and α1-γ2L sites combined.
However, the results may also be explained by the α1A36
′F
mutation being ineffective in preventing ivermectin binding
to the α1-β2 or α1-γ2L sites. We investigated this possibility
in two-ways. First, we expressed α1A36
′Fβ2γ2LS36
′F GABAARs
which should contain no functional ivermectin sites (Figure 6C).
If, on the other hand, the α1-β2 or α1-γ2L sites retain some
residual functionality then this receptor should exhibit detectable
ivermectin sensitivity. However, as shown in Figures 6D,E,
no effect of ivermectin was observed at any concentration at
α1A36
′Fβ2γ2LS36
′F GABAARs.
Properties of Binary α1β2 GABAARs
The second control experiment was to investigate the binary
α1β2 GABAAR which exists in an obligatory α1-β2-α1-
β2-β2 stoichiometry (Baumann et al., 2001). This receptor
should thus have two functional α1-β2 ivermectin sites per
pentamer (Figure 7A). As indicated in the sample recording
in Figure 7B and in the averaged data plotted below, these
receptors exhibited significant ivermectin-mediated potentiation
of GABA-gated currents with a concentration-response profile
indistinguishable from that of α1β2γ2LS36
′F GABAARs, but
exhibited no irreversible ivermectin activation. As a negative
control for this experiment we also tested α1A36
′Fβ2 GABAARs,
which like α1A36
′Fβ2γ2LS36
′F GABAARs, should contain no
functional ivermectin sites (Figure 7C). As predicted, this
receptor exhibited no ivermectin sensitivity at all, even at
concentrations up to 30µM (Figures 7D, E). Taken together,
results from Figures 6, 7 indicate that the α1A36
′F mutation
completely eliminates ivermectin binding at the α1-β2 and
α1-γ2L interface sites. Thus, we conclude that the maximum
efficacy with which ivermectin potentiates GABA-gated currents
is similar for receptors incorporating a single γ2L-β2 interface
site as it is in receptors incorporating α1-β2 and α1-γ2L
interface sites combined. We also conclude that irreversible
ivermectin activation requires a functional γ2L-β2 interface
site.
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FIGURE 5 | Effects of ivermectin on α1A36
′Fβ2γ2L GABAARs. (A) Structural model showing the location of the single ivermectin binding site. (B) Sample
recording showing the effect of increasing ivermectin concentrations on EC3 GABA-gated currents, with reversible (i.e., GABA-activated) and irreversible
current increases indicated. (C) Mean concentration-response relationship of the reversible current component, compared with the corresponding wild type
GABAAR data from Figure 1. (D) Mean concentration-response relationship of the irreversible current component, compared with the corresponding wild
type GABAAR data from Figure 1. (E) Mean saturating magnitudes of reversible and irreversible ivermectin-modulated currents (defined as indicated in B),
and their sum, plotted as a percentage of EC3 GABA-activated current, and compared to corresponding wild type data. *Represents significance of t-test
P < 0.05.
Properties of GABAARs Incorporating Mutant
β2-M36′A Subunits
To help validate the role of 36′ sidechains in forming ivermectin
sites, we investigated the functional properties of GABAARs
incorporating the β2M36
′A mutation. We first characterized
the ivermectin sensitivity of the α1β2M36
′Aγ2L GABAAR
which should incorporate five ivermectin sites per pentamer
(Figure 8A). The effects of increasing ivermectin concentrations
on EC3 GABA-gated currents in this receptor revealed significant
potentiation of GABA-gated currents but no irreversible
activation (Figure 8B). The averaged ivermectin concentration-
response relationship demonstrates that the magnitude of the
reversible potentiation to be significantly smaller than that
observed at the wild type receptor (Figure 8E) although it was
not significantly different to that observed at α1β2γ2LS36
′F or
α1A36
′Fβ2γ2L GABAARs (P > 0.05 unpaired t-tests). This result
was unexpected for two reasons. First, despite a presumably
intact γ2L-β2 binding site, it exhibited no irreversible ivermectin
activation, apparently contradicting our conclusion from the
previous section. Second, it seems surprising that receptors
with five ivermectin sites should yield a reduced ivermectin
efficacy relative to wild type receptors which have only three
sites. We then investigated the α1A36
′Fβ2M36
′Aγ2LS36
′
GABAAR,
which should incorporate ivermectin sites at the two β2-α1
interfaces only (Figure 8C). As shown in the sample recording
(Figure 8D) and in the averaged concentration-response data
(Figure 8E), EC10 GABA-gated currents were strongly inhibited
by ivermectin. This unexpected result provides a possible
explanation as to why the ivermectin potentiating and direct
activation efficacy at α1β2M36
′Aγ2L GABAARs was reduced
relative to wild type GABAARs.
Quantitating the Magnitude of
Ivermectin-activated Currents by Picrotoxin
Block
In a final set of experiments, we sought to confirm the
relative magnitudes of the irreversible ivermectin-gated currents
in α1β2γ2L, α1A36
′Fβ2γ2L, and α1β2γ2LS36
′F GABAARs using
picrotoxin block. Our approach involved applying 30µM
ivermectin until maximal activation was achieved, and then
blocking this current with 100µM picrotoxin (Figure 9A).
The mean picrotoxin-blocked current was then expressed
as a percentage of the saturating GABA-activated current,
and compared to the irreversible ivermectin-activated current
magnitude replotted from Figure 5E. The averaged results
(Figure 9B), confirm that ivermectin activates irreversible
currents in the α1β2γ2L and α1A36
′Fβ2γ2L GABAARs but not in
the α1β2γ2LS36
′F GABAAR.
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FIGURE 6 | Effects of ivermectin on α1β2γ2LS36
′F and α1A36
′Fβ2γ2LS36
′F GABAARs. (A) Structural model of α1β2γ2L
S36′F showing the location of the
ivermectin binding sites. (B) Sample recording showing the effect of increasing ivermectin concentrations on EC3 GABA-gated currents in α1 β2γ2L
S36′F GABAARs.
(C) Structural model of α1A36
′Fβ2γ2LS36
′F showing the lack of ivermectin binding sites. (D) Sample recording showing the effect of increasing ivermectin
concentrations on EC10 GABA-gated currents in α1
A36′Fβ2γ2LS36
′F GABAARs. (E) Mean concentration-response data for the experiments as shown in (B,D).
*Represents significance of t-test P < 0.05.
Discussion
Validation of Mutagenesis Approach
An overarching hypothesis of this study is that the ability of
ivermectin to bind to a specific interface is determined by
the sidechain volume of 36′ residue on the + side of that
interface. We have shown using binary α1A36
′Fβ2 receptors that
the α1A36
′F mutation eliminates ivermectin sensitivity at α1-β2
interfaces. We have also shown, via the ternary α1A36
′Fβ2γ2LS36
′F
receptor, that 36′F mutations eliminate ivermectin sensitivity
at the α1-γ2L and γ2L-β2 interfaces. We also performed
the reverse control experiment whereby we introduced the
β2M36
′A mutation into ivermectin-insensitive α1A36
′Fβ2γ2LS36
′F
receptors to create ivermectin sensitivity where previously there
was none (Figure 8E). Hence, as with GlyRs and GluClRs
(Lynagh and Lynch, 2010), a bulky 36′F sidechain eliminates
ivermectin binding, whereas a small sidechain (36′G, 36′A, or
36′S) is conducive to ivermectin binding. Thus, 36′ sidechain
volume is a useful means of controlling ivermectin binding to
particular interfaces in GABAARs.
Main Findings
Our first main finding concerns the relationship between the
efficacy with which ivermectin potentiates EC3 GABA-gated
currents and the number of functional ivermectin sites per
receptor. Wild type α1β2γ2L GABAARs, which show greatest
efficacy, incorporate three ivermectin sites. GABAARs that
incorporate two native ivermectin sites (i.e., the α1β2γ2LS36
′F
and α1β2 receptors) show a correspondingly reduced level of
ivermectin efficacy. However, the α1A36
′Fβ2γ2L GABAAR, which
contains a single ivermectin site at the γ2L-β2 interface, has
an efficacy similar to that of receptors containing two sites.
This suggests the γ2L-β2 interface site is more allosterically
active. One possibility is that bound ivermectin induces a large
conformational and/or energetic change here that perhaps also
locks ivermectin into the pocket thereby causing irreversible
activation. In support to this hypothesis, our docking analysis
shows more residues interacting with ivermectin on the γ2L (+)
side in comparison with the α1 (+) side, which should enhance
the stability of ivermectin binding (Figure 2C).
Our second main finding is that the irreversible activating
effect of ivermectin requires a functional ivermectin site at
the γ2L-β2 interface. Is there a molecular explanation for
this apparently strong binding interaction? In their GluClR-
ivermectin crystal structure, Hibbs and Gouaux originally
concluded that ivermectin bound via H-bonds with Q-26′, S15′,
and T40′ and Van der Waals interactions with several other
residues (Hibbs and Gouaux, 2011). Of the H-bonding residues,
α1 and γ2L subunits both contain Q-26′ and S15′ residues,
and consequently they are unlikely to specifically mediate the
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FIGURE 7 | Effects of ivermectin on α1β2 and α1A36
′Fβ2 GABAARs. (A) Structural model of α1β2 showing the location of the ivermectin binding sites. (B)
Sample recording showing the effect of increasing ivermectin concentrations on EC10 GABA-gated currents in α1β2 GABAARs. (C) Structural model of α1
A36′Fβ2
showing the lack of ivermectin binding sites. (D) Sample recording showing the effect of increasing ivermectin concentrations on EC10 GABA-gated currents
α1A36
′Fβ2 GABAARs. (E) Mean concentration-response data for the experiments as shown in (B,D). *Represents significance of t-test P < 0.05.
differential effect. On the other hand, α1 has a 40′A whereas γ2L
has a 40′I, although neither of these residues contribute to H-
bonds. In any case, the importance of any putative H-bonding
by 40′ residues has been questioned (Lynagh and Lynch, 2012a).
The irreversible binding effect of ivermectin in the γ2L-β2
interface site is thus more likely to be due to the additional weak
interactions in the binding pocket, rather than to the presence or
absence of specific strong binding interactions. This fits well with
our modeling results (Figure 3) which propose that the γ2L-β2
interface shows a greater number of residues contributing polar
contacts which should tighten the pocket around the ivermectin
molecule.
If ivermectin binds irreversibly via the γ2L-β2 interface site as
we conclude above, then why does the α1β2M36
′Aγ2L GABAAR
exhibit no detectable irreversible ivermectin activation? We
suggest this might be due to the presence of the decrypted
ivermectin site at the β2M36
′A-α1 interface. This site, which in
isolation mediates ivermectin inhibition of GABA-gated currents
(Figure 8E), may either exert a closing effect on the channel
to counter the irreversible activation, or it might allosterically
interact with the γ2L-β2 site to render it non-functional. These
possibilities would be difficult to separate experimentally. The
observed reduction in the efficacy of ivermectin potentiation
of reversible EC3 GABA-gated currents at the α1β2M36
′Aγ2L
GABAAR might be explained similarly (Figure 8E). An alternate
possibility is that the mutant β2M36
′A subunit impairs expression
of the γ2L subunit, which would also eliminate the irreversible
ivermectin binding site.
Our third main finding is that ivermectin inhibits GABA-
gated currents by binding to decrypted β2M36
′A-α1 interface
binding sites in the α1A36
′Fβ2M36
′Aγ2LS36
′F GABAAR. As these
sites are lined by the M2 and M3 domains from the β2 subunit
and the M1 domain from the α1 subunit, M1 residues that are
not conserved between α1 and β2 or γ2, or M2/3 residues that
are not conserved between β2 and α1 or γ2, could be key to
forming inhibitory ivermectin sites. These criteria are satisfied by
two putative ivermectin H-bonding residues (β215
′N and β240
′V)
plus several other residues that contribute weak interactions
to bound ivermectin (α1−19
′M, α1−22
′P, α1−23
′L, α1−27
′I, and
β233
′M). According to our modeling, all but one of these residues
contacts ivermectin (Figure 3). As other non-conserved residues
in the TM domains could also be important in terms of altering
the overall shape of the pocket, the molecular elements essential
for conferring the inhibitory action of ivermectin at the β2M36
′A-
α1 interface may be difficult to isolate.
Inhibitory effects of ivermectin have previously been
characterized in other pLGICs. For example, in the α1 GlyR
it was shown that bulky tryptophan substitutions to residues
midway down the M1 domain (L-19′W) or M3 domain
(L39′W) convert ivermectin from an agonist into an inhibitor of
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FIGURE 8 | Effects of ivermectin on α1β2M36
′Aγ2L and α1A36
′Fβ2M36
′Aγ2LS36
′F GABAARs. (A) Structural model of α1β2
M36′Aγ2L showing the location of the
ivermectin binding sites. (B) Sample recording showing the effect of increasing ivermectin concentrations on EC3 GABA-gated currents in α1β2
M36′Aγ2L GABAARs.
(C) Structural model of α1A36
′Fβ2M36
′Aγ2LS36
′F showing the location of the single ivermectin binding site. (D) Sample recording showing the inhibitory effect of
increasing ivermectin concentrations on EC10 GABA-gated currents in α1
A36′Fβ2M36
′Aγ2LS36
′F GABAARs. (E) Mean concentration-response data for the
experiments as shown in (B). (F) Mean concentration-response data for the experiments as shown in (D). *Represents significance of t-test P < 0.05.
glycine-activated currents (Lynagh et al., 2011). Similar effects
have been observed in α7 nAChRs incorporating mutations to
residues in the M1, M2, or M3 domains (S-17′M, M15′L, and
S37′V, respectively; Collins and Millar, 2010). In the Drosophila
RDL pLGIC, ivermectin was converted into an inhibitor by a
variety of single mutations including A2′C, A2′S, A2′N, G34′T,
V38′Q, and V38′N (Nakao et al., 2015). Taken together, the broad
distribution of these residues provides few clues as to specific
elements responsible for ivermectin inhibition at the β2M36
′A-α1
interface. Again, the inhibitory effect of ivermectin could be due
to the overall shape of the binding pocket, and the nature of the
conformational change that occurs when it is occupied.
Binding of Other Molecules in and Near the
Ivermectin Site
The 36′ position has been implicated in alcohol and anesthetic
specific modulation (Mascia et al., 2000), as well as neurosteroids
(Akk et al., 2007; Li et al., 2009) and even cholesterol (Hénin
et al., 2014). Ivermectin “wedges” between the M3 helix of the
principal subunit and the M1 helix of the complimentary subunit
of the GluClR to stabilize the wide-open pore conformation
(Hibbs andGouaux, 2011), and the access to this inter-membrane
binding pocket is granted (or not) by the residue occupying
the M3 36′ position. Ivermectin removal was first predicted
to shrink the GluClR pore radius to 1.2 Å (Yoluk et al.,
2013). Subsequent publication of the GluClR crystal structure in
the apo-conformation not only supported this model but also
showed that other hydrophobic molecules including membrane
phospholipids are able to interact with this pocket to modulate
the pore (Althoff et al., 2014). If this pocket is accessible to
phospholipids, endogenous neurosteroids or cholesterol, then
ivermectin may be able to compete with and displace some of
these molecules with a potency that may vary from one interface
to the next.
The cooperative effect between transmembrane interfaces
has previously been showed in the human α1β3γ2 GABAAR
by the use of a potent stereospecific photoreactive modified
barbiturate in combination with the anesthetic etomidate (Chiara
et al., 2013). The barbiturate did not photolabel the etomidate-
binding site located at the β3-α1 interface, but instead it did
so at the α1-β3 and γ2-β3 interfaces involving, among others,
some of the residues that contribute to ivermectin sensitivity.
Each ligand (etomidate and the photoreactive barbiturate) could
enhance the photo-incorporation of the other, demonstrating
allosteric interactions between sites, and potentiating their effect
in combination. This mechanism was hypothesized to bypass
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FIGURE 9 | Picrotoxin block of currents directly activated by ivermectin. (A) Examples of ivermectin activation and picrotoxin block of GABAARs
comprising the indicated subunits. (B) Averaged picrotoxin block data from (A) compared with averaged ivermectin irreversible activation data from Figure 5E.
All results were averaged from at least 4 cells. This confirms that direct ivermectin activation requires receptors with intact γ2L-β2 interfaces. *Represents
significance of t-test P < 0.05.
the extracellular domain-transmembrane domain allosteric
coupling regulated by the binding of the neurotransmitter
to its orthosteric-binding site (Sauguet et al., 2015). The
results we present here may also be interpreted in the same
manner.
Conclusion
We show that ivermectin binds to α1-β2, α1-γ2L, and γ2L-β2
subunit interface sites in α1β2γ2L GABAARs. These binding sites
are not equivalent. For example, ivermectin produces irreversible
channel activation only when it binds to the γ2L-β2 interface
site. When it binds to α1-β2 sites it elicits potentiation of
GABA-gated currents but has no irreversible activating effect.
Ivermectin cannot bind in the β2-α1 interface binding site due
to a bulky methionine sidechain at the M3 36′ position that
blocks access to the ivermectin pocket. Introducing a small
alanine residue at this interface (M36′A) creates a functional
ivermectin site, but surprisingly it is inhibitory with bound
ivermectin reducing the magnitude of GABA-gated currents.
Our molecular modeling simulations predict that ivermectin
binds in a common orientation at each interface, although it
is coordinated by a larger number of molecular interactions at
the γ2L-β2 interface site than at any other interface. This may
explain why ivermectin binds irreversibly here. Overall, this study
demonstrates unexpectedly stark pharmacological differences
among the ivermectin binding sites in GABAARs that cannot
easily be explained by non-conserved residues in or around these
sites. Rather, these results provide evidence that the ivermectin
sites have subtly different structures and occupation of them
by ivermectin induces subtly different conformational changes
that modulate channel function in different ways. Understanding
these structural and conformational subtleties could provide
insights into the development of new drugs for a variety of
neurological conditions.
Author Contributions
AE-M conducted all experiments, analyzed the data and wrote
the manuscript. JL designed the project, analyzed the data and
wrote the manuscript.
Funding
This project was supported by the Australian Research Council
(LP120100297, DP120104373) and the National Health and
Medical Research Council of Australia (1058542, 1060707). AE
was supported by a University of Queensland Postdoctoral
Research Fellowship.
Acknowledgments
We thank Dr. Angelo Keramidas for helpful suggestions
throughout the project and for comments on the manuscript.
Frontiers in Molecular Neuroscience | www.frontiersin.org 12 September 2015 | Volume 8 | Article 55
Estrada-Mondragon and Lynch GABA(A) receptor ivermectin binding sites
References
Adelsberger, H., Lepier, A., and Dudel, J. (2000). Activation of rat recombinant
alpha(1)beta(2)gamma(2S) GABA(A) receptor by the insecticide
ivermectin. Eur. J. Pharmacol. 394, 163–170. doi: 10.1016/S0014-2999(00)
00164-3
Akk, G., Covey, D. F., Evers, A. S., Steinbach, J. H., Zorumski, C. F., andMennerick,
S. (2007). Mechanisms of neurosteroid interactions with GABA(A) receptors.
Pharmacol. Ther. 116, 35–57. doi: 10.1016/j.pharmthera.2007.03.004
Althoff, T., Hibbs, R. E., Banerjee, S., and Gouaux, E. (2014). X-ray structures of
GluCl in apo states reveal a gating mechanism of Cys-loop receptors. Nature
512, 333–337. doi: 10.1038/nature13669
Baumann, S. W., Baur, R., and Sigel, E. (2001). Subunit arrangement of gamma-
aminobutyric acid type a receptors. J. Biol. Chem. 276, 36275–36280. doi:
10.1074/jbc.M105240200
Campbell, W. C. (2012). History of avermectin and ivermectin, with
notes on the history of other macrocyclic lactone antiparasitic agents.
Curr. Pharm. Biotechnol. 13, 853–865. doi: 10.2174/138920112800
399095
Chiara, D. C., Jayakar, S. S., Zhou, X., Zhang, X., Savechenkov, P. Y., Bruzik,
K. S., et al. (2013). Specificity of intersubunit general anesthetic-binding sites
in the transmembrane domain of the human alpha1beta3gamma2 gamma-
aminobutyric acid type A (GABAA) receptor. J. Biol. Chem. 288, 19343–19357.
doi: 10.1074/jbc.M113.479725
Collins, T., and Millar, N. S. (2010). Nicotinic acetylcholine receptor
transmembrane mutations convert ivermectin from a positive to
a negative allosteric modulator. Mol. Pharmacol. 78, 198–204. doi:
10.1124/mol.110.064295
Crump, A., and Omura, S. (2011). Ivermectin, ‘wonder drug’ from Japan: the
human use perspective. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 87, 13–28. doi:
10.2183/pjab.87.13
Gallagher, M. J., Song, L., Arain, F., and Macdonald, R. L. (2004). The juvenile
myoclonic epilepsy GABA(A) receptor alpha1 subunit mutation A322D
produces asymmetrical, subunit position-dependent reduction of heterozygous
receptor currents and alpha1 subunit protein expression. J. Neurosci. 24,
5570–5578. doi: 10.1523/JNEUROSCI.1301-04.2004
Henin, J., Salari, R., Murlidaran, S., and Brannigan, G. (2014). A predicted binding
site for cholesterol on the GABAA receptor. Biophys. J. 106, 1938–1949. doi:
10.1016/j.bpj.2014.03.024
Hibbs, R. E., and Gouaux, E. (2011). Principles of activation and permeation
in an anion-selective Cys-loop receptor. Nature 474, 54–60. doi:
10.1038/nature10139
Khakh, B. S., Proctor, W. R., Dunwiddie, T. V., Labarca, C., and Lester, H. A.
(1999). Allosteric control of gating and kinetics at P2X(4) receptor channels.
J. Neurosci. 19, 7289–7299.
Krause, R. M., Buisson, B., Bertrand, S., Corringer, P. J., Galzi, J. L., Changeux, J.
P., et al. (1998). Ivermectin: a positive allosteric effector of the alpha7 neuronal
nicotinic acetylcholine receptor.Mol. Pharmacol. 53, 283–294.
Krüsek, J., and Zemková, H. (1994). Effect of ivermectin on gamma-aminobutyric
acid-induced chloride currents in mouse hippocampal embryonic
neurones. Eur. J. Pharmacol. 259, 121–128. doi: 10.1016/0014-2999(94)
90500-2
Li, G. D., Chiara, D. C., Cohen, J. B., and Olsen, R. W. (2009). Neurosteroids
allosterically modulate binding of the anesthetic etomidate to gamma-
aminobutyric acid type a receptors. J. Biol. Chem. 284, 11771–11775. doi:
10.1074/jbc.C900016200
Lynagh, T., and Lynch, J. W. (2010). A glycine residue essential for high ivermectin
sensitivity in Cys-loop ion channel receptors. Int. J. Parasitol. 40, 1477–1481.
doi: 10.1016/j.ijpara.2010.07.010
Lynagh, T., and Lynch, J. W. (2012a). Ivermectin binding sites in human and
invertebrate Cys-loop receptors. Trends Pharmacol. Sci. 33, 432–441. doi:
10.1016/j.tips.2012.05.002
Lynagh, T., and Lynch, J. W. (2012b). Molecular mechanisms of Cys-loop ion
channel receptor modulation by ivermectin. Front. Mol. Neurosci. 5:60. doi:
10.3389/fnmol.2012.00060
Lynagh, T., Webb, T. I., Dixon, C. L., Cromer, B. A., and Lynch, J.
W. (2011). Molecular determinants of ivermectin sensitivity at the
glycine receptor chloride channel. J. Biol. Chem. 286, 43913–43924. doi:
10.1074/jbc.M111.262634
Mascia, M. P., Trudell, J. R., and Harris, R. A. (2000). Specific binding sites for
alcohols and anesthetics on ligand-gated ion channels. Proc. Natl. Acad. Sci.
U.S.A. 97, 9305–9310. doi: 10.1073/pnas.160128797
Nakao, T., Banba, S., and Hirase, K. (2015). Comparison between the modes
of action of novel meta-diamide and macrocyclic lactone insecticides on
the RDL GABA receptor. Pestic. Biochem. Physiol. 120, 101–108. doi:
10.1016/j.pestbp.2014.09.011
Olsen, R. W., and Sieghart, W. (2009). GABA A receptors: subtypes provide
diversity of function and pharmacology. Neuropharmacology 56, 141–148. doi:
10.1016/j.neuropharm.2008.07.045
Sali, A., and Blundell, T. L. (1993). Comparative protein modelling by satisfaction
of spatial restraints. J. Mol. Biol. 234, 779–815. doi: 10.1006/jmbi.1993.1626
Sauguet, L., Shahsavar, A., and Delarue, M. (2015). Crystallographic
studies of pharmacological sites in pentameric ligand-gated ion
channels. Biochim. Biophys. Acta 1850, 511–523. doi: 10.1016/j.bbagen.
2014.05.007
Schrodinger, L. L. C. (2010). The PyMOLMolecular Graphics System, Version 1.3r1.
Shan, Q., Haddrill, J. L., and Lynch, J. W. (2001). Ivermectin, an unconventional
agonist of the glycine receptor chloride channel. J. Biol. Chem. 276,
12556–12564. doi: 10.1074/jbc.M011264200
Sieghart, W., and Sperk, G. (2002). Subunit composition, distribution and function
of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2, 795–816. doi:
10.2174/1568026023393507
Sigel, E., and Baur, R. (1987). Effect of avermectin B1a on chick neuronal
gamma-aminobutyrate receptor channels expressed in Xenopus oocytes. Mol.
Pharmacol. 32, 749–752.
Wolstenholme, A. J., and Rogers, A. T. (2005). Glutamate-gated chloride
channels and the mode of action of the avermectin/milbemycin anthelmintics.
Parasitology 131(Suppl.), S85–S95. doi: 10.1017/s0031182005008218
Yoluk, O., Brömstrup, T., Bertaccini, E. J., Trudell, J. R., and Lindahl, E. (2013).
Stabilization of the GluCl ligand-gated ion channel in the presence and absence
of ivermectin. Biophys. J. 105, 640–647. doi: 10.1016/j.bpj.2013.06.037
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Estrada-Mondragon and Lynch. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 September 2015 | Volume 8 | Article 55
